Aiming for Burst Suppression in Treating Refractory Status Epilepticus: Probably Not.

Neurology

From the Grey Bruce Health Services (G.B.Y.), Owen Sound, Ontario, Canada; and Comprehensive Epilepsy Center KS 457 (F.W.D.), Beth Israel Deaconess Medical Center Boston, MA.

Published: May 2023

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000207290DOI Listing

Publication Analysis

Top Keywords

aiming burst
4
burst suppression
4
suppression treating
4
treating refractory
4
refractory status
4
status epilepticus
4
aiming
1
suppression
1
treating
1
refractory
1

Similar Publications

SEEG seizure onset patterns in mesial temporal lobe epilepsy: A cohort study with 76 patients.

Neurophysiol Clin

January 2025

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR China. Electronic address:

Objectives: In the present study with a large cohort, we aimed to characterize intracerebral seizure onset patterns (SOP) of mesial temporal lobe epilepsy (mTLE), with or without hippocampal sclerosis (HS) as identified via magnetic resonance imaging (MRI).

Methods: We retrospectively analyzed 255 seizures of 76 consecutive patients with mTLE explored by stereoelectroencephalography (SEEG), including HS-mTLE (n = 52) and non-HS- mTLE (n = 24). Relevant results were obtained by a combination of spectral analysis and manual review.

View Article and Find Full Text PDF

Background And Objective: The Scania Accelerated Intermittent Theta-burst Implementation Study (SATIS) aimed to investigate the tolerability, preliminary effectiveness, and practical feasibility of an accelerated intermittent theta burst stimulation (aTBS) protocol in treating depression.

Methods: We used an open-label observational design, recruiting 20 patients (aged 19-84 years) from two public brain stimulation centers in Sweden. During the five-day treatment period and at a follow-up visit after 30 days we closely monitored adverse events and collected self-rated side effect data.

View Article and Find Full Text PDF
Article Synopsis
  • Acinetobacter baumannii, especially the carbapenem-resistant strains (CRAB), is a critical pathogen linked to antimicrobial resistance (AMR) and is prioritized by the WHO.
  • Phage therapy is being explored as a potential treatment for CRAB infections due to increasing resistance to conventional antibiotics.
  • A newly isolated lytic phage, vAbaIN10, exhibits effective lytic activity against CRAB in various conditions and shows promise in advancing treatment options for multidrug-resistant infections.
View Article and Find Full Text PDF

Purpose: Our study aimed to assess the effects of anticancer 4-thiazolidinone-based free water-insoluble therapeutics Les-3288 and Les-3833 and their waterborne complexes with branched PEG-containing polymeric carriers (A24-PEG550 and A24-PEG750) on immune response.

Methods: Human peripheral blood was used to study in vitro lymphocyte proliferative function, leukocyte phagocytic activity and respiratory burst, and cytokine production.

Results: The binding of the polymer to the anticancer drug Les-3288, which is intended to mitigate the immunosuppressive effects of the free drug on the proliferative activity of T lymphocytes and T-dependent B cells, demonstrated comparable efficacy for both A24-PEG750 and A24-PEG550 nanocarriers.

View Article and Find Full Text PDF

Background: Major depressive disorder (MDD) is prevalent among older patients and is frequently associated with cognitive decline and a reduced quality of life. Non-invasive brain stimulation (NIBS) techniques show promise for treating MDD, but their comparative efficacy and safety older populations remain unclear. This study aimed to compare the efficacy and cognitive effects of various NIBS techniques in treating MDD in older patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!